Herpes zoster generalisatus bei Diabetes mellitus

Graue, N.; Grabbe, S.; Dissemond, Joachim

doi:10.1055/s-2006-932529

Cited by 13 publications

(3 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Malignancy is associated with reactivation of chronic persistent viruses such as varicella zoster virus (VZV) (Whiteside, 2006), causing significant morbidity and mortality (Wade, 2006). Herpes zoster is more common in patients with malignancies (Schmader, 2001;Sorensen et al, 2004) and may lead to severe disease with multi-dermatomal involvement and visceral dissemination, which can be lethal (Gallagher and Merigan, 1979;Onunu and Uhunmwangho, 2004;Hackanson et al, 2005;Graue et al, 2006). However, apart from clinically apparent VZV reactivation, subclinical reactivation has also been reported in both immunocompetent and immunosuppressed individuals (Schunemann et al, 1998;Quinlivan et al, 2007).…”

mentioning

confidence: 99%

IE63-specific T-cell responses associate with control of subclinical varicella zoster virus reactivation in individuals with malignancies

et al. 2010

View full text Add to dashboard Cite

BACKGROUND: Reactivation of the varicella zoster virus (VZV) is more common in patients with malignancies; however, the molecular and cellular mechanisms underlying this susceptibility are unclear. METHODS: Using ex vivo interferon-g ELISpot assays, we set out to analyse VZV-specific immune responses in a large cohort of patients with malignancies. RESULTS: We observed that patients with malignancies had impaired VZV-specific T-cell responses, particularly in those with haematological malignancies and breast carcinoma. Immediate-early protein 63 (IE63)-specific T-cell responses were significantly impaired in those with subclinical VZV re-activation. Malignancy is associated with reactivation of chronic persistent viruses such as varicella zoster virus (VZV) (Whiteside, 2006), causing significant morbidity and mortality (Wade, 2006). Herpes zoster is more common in patients with malignancies (Schmader, 2001;Sorensen et al, 2004) and may lead to severe disease with multi-dermatomal involvement and visceral dissemination, which can be lethal (Gallagher and Merigan, 1979;Onunu and Uhunmwangho, 2004;Hackanson et al, 2005;Graue et al, 2006). However, apart from clinically apparent VZV reactivation, subclinical reactivation has also been reported in both immunocompetent and immunosuppressed individuals (Schunemann et al, 1998;Quinlivan et al, 2007). Although the mechanisms underlying such reactivation are unclear, it is thought that cell-mediated immune responses are vital in controlling VZV replication (Malavige et al, , 2008b.VZV glycoproteins I and E, immediate-early protein 63 (IE63) and four specific CD4 þ T cells have been shown to circulate at persistently high frequencies in the peripheral blood of healthy seropositive donors without a history of reactivation (Jones et al, 2006Malavige et al, 2007Malavige et al, , 2008a. However, VZV-specific T-cell responses have been shown to be lower in elderly individuals and in patients with disease such as systemic lupus erythematosus (Miller, 1980;Levin et al, 2003;Park et al, 2004). As these groups of individuals are at a higher risk of herpes zoster, it seems that VZVspecific T cells are important in preventing virus reactivation. Some important studies conducted earlier have indeed shown that suppression of VZV-specific cellular immunity preceded the occurrence of herpes zoster (Arvin et al, 1978(Arvin et al, , 1980. However, with a more detailed understanding of VZV protein-specific responses, we can now study the mechanisms that are important in preventing virus reactivation. Therefore, we set out to analyse the overall VZV-specific immune responses and the immune responses to VZV IE63 and gE proteins, in a cohort of patients with malignancies to identify the associations with viral reactivation. MATERIALS AND METHODSFresh heparinised venous blood samples were obtained from 106 adult individuals with malignancies (before receiving chemotherapy) who were admitted to the Cancer Institute in Sri Lanka with a past history of primary VZV infection. Samples were also obt...

show abstract

mentioning

confidence: 99%

IE63-specific T-cell responses associate with control of subclinical varicella zoster virus reactivation in individuals with malignancies

et al. 2010

View full text Add to dashboard Cite

show abstract

“…12 Short-term elevated blood glucose levels also affect the immune response, which suggesting that poor glycemic control favors the spread of VZV. 13 In addition, hypertension, hyperlipidemia, untimely treatment, and statins are also risk factors for HZ recurrence, which can lead to VZV reactivation. 14 Drugs approved in Europe for the systemic treatment of herpes zoster are acyclovir, penciclovir, valacyclovir, famciclovir, brivudine.…”

Section: Discussionmentioning

confidence: 99%

Case report: Relapsed disseminated cutaneous herpes zoster successfully treated with brivudine

Feng,

Zhang,

Zhang

2023

Eur J Inflamm

View full text Add to dashboard Cite

A 64-year-old man presented with painful rash on the trunk and extremities for more than half a month. Nephrotic syndrome had been diagnosed 2 years ago and had been regularly treated with glucocorticoids and immunosuppressants. He developed herpes zoster 1 year ago. Laboratory investigation demonstrated varicella-zoster virus DNA (VZV-DNA), varicella-zoster virus IgM (VZV-IgM), and varicella-zoster virus antibody IgG (VZV-IgG) were all positive. After the clinical diagnosis of relapsed disseminated cutaneous herpes zoster had been confirmed, systemic therapy with brivudine 125 mg everyday was started.

show abstract

“…In a group of 107 patients with HZ, HHZ was diagnosed in three cases. 4 HHZ usually occurs in immunocompromised patients because of chronic polyarthritis, 5 colon carcinoma, 6 Evans syndrome, 6 diabetes, 7 kidney transplant, 8 idiopathic thrombocytopenic purpura, 9 rheumatoid arthritis. 10 , 11 In addition, several patients were in therapy with systemic corticosteroids 5 , 8 , 9 , 11 or methotrexate.…”

Section: Figurementioning

confidence: 99%

Four cases of hemorrhagic herpes zoster associated with dabigatran therapy

Veraldi

Beretta

Spigariolo

2022

Dermatologic Therapy

View full text Add to dashboard Cite

In 2015, we reported three patients in therapy with clopidogrel who developed hemorrhagic herpes zoster (HHZ). 1 In the last months, we observed four patients with HHZ who were in therapy with dabigatran, an oral anticoagulant. This drug acts by inhibiting free and fibrin-bound thrombin. 2 It was initially approved to prevent embolisms in patients with non-valvular atrial fibrillation. 2 Dabigatran showed to be effective and well tolerated: esophagitis, gastrointestinal hemorrhages, myocardial infarction, hepatitis, nephritis and allergic reactions are rare side effects. 2 Furthermore, coagulation monitoring is unnecessary. 2 To our knowledge, only one case 3 of HHZ associated with dabigatran therapy was reported in the literature.The patients were four Caucasian females aged 73, 69, 85, and 69 years, respectively, in therapy with dabigatran (150-220 mg/day) for 3-8 weeks. Two patients were subjected to recent hip or knee arthroplasty; two patients were affected by peripheral arterial dis-

show abstract

Herpes zoster generalisatus bei Diabetes mellitus

Cited by 13 publications

References 7 publications

IE63-specific T-cell responses associate with control of subclinical varicella zoster virus reactivation in individuals with malignancies

IE63-specific T-cell responses associate with control of subclinical varicella zoster virus reactivation in individuals with malignancies

Case report: Relapsed disseminated cutaneous herpes zoster successfully treated with brivudine

Four cases of hemorrhagic herpes zoster associated with dabigatran therapy

Contact Info

Product

Resources

About